CR10186A - Inhibidores de 11-beta-hsd1 - Google Patents

Inhibidores de 11-beta-hsd1

Info

Publication number
CR10186A
CR10186A CR10186A CR10186A CR10186A CR 10186 A CR10186 A CR 10186A CR 10186 A CR10186 A CR 10186A CR 10186 A CR10186 A CR 10186A CR 10186 A CR10186 A CR 10186A
Authority
CR
Costa Rica
Prior art keywords
beta
hsd1 inhibitors
hsd1
inhibitors
inhibition
Prior art date
Application number
CR10186A
Other languages
English (en)
Inventor
Jason Shaoyun Xiang
Eddine Saiah
Steve Y Tam
John C Mckew
Lihren Chen
Manus Ipek
Katherine Lee
Huan-Qui Li
Jianchang Li
Wei Li
Tarek Suhayl Mansour
Vipin Suri
Richard Vargas
Yuchuan Wu
Zhao-Kui Wan
Jinbo Lee
Eva Binnun
Douglas P Wilson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR10186A publication Critical patent/CR10186A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Esta invención se refiere a la inhibición de 11B-HSD1.
CR10186A 2006-02-07 2008-07-30 Inhibidores de 11-beta-hsd1 CR10186A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77126206P 2006-02-07 2006-02-07

Publications (1)

Publication Number Publication Date
CR10186A true CR10186A (es) 2008-10-29

Family

ID=38236242

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10186A CR10186A (es) 2006-02-07 2008-07-30 Inhibidores de 11-beta-hsd1

Country Status (18)

Country Link
US (2) US7632838B2 (es)
EP (1) EP1981848A2 (es)
JP (1) JP2009526059A (es)
KR (1) KR20080093072A (es)
CN (1) CN101400653A (es)
AR (1) AR059355A1 (es)
AU (1) AU2007212429A1 (es)
BR (1) BRPI0707537A2 (es)
CA (1) CA2641609A1 (es)
CR (1) CR10186A (es)
GT (1) GT200800151A (es)
IL (1) IL193157A0 (es)
NO (1) NO20083492L (es)
PA (1) PA8713501A1 (es)
PE (1) PE20071232A1 (es)
RU (1) RU2008132333A (es)
TW (1) TW200800898A (es)
WO (1) WO2007092435A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8713501A1 (es) 2006-02-07 2009-09-17 Wyeth Corp INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
AU2007231594A1 (en) * 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
WO2007135427A1 (en) * 2006-05-23 2007-11-29 Astrazeneca Ab 1,4-disubstituted piperazine and 1,4-disubstituted azepane as 11 -beta-hydroxysteroid dehydrogenase 1 inhibitors
CL2007003223A1 (es) * 2006-11-10 2008-01-11 Wyeth Corp Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
RU2009130576A (ru) * 2007-02-07 2011-03-20 Вайет (Us) Способ приготовления галогенированных аминов
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2008302570B2 (en) 2007-09-20 2012-05-31 Irm Llc Compounds and compositions as modulators of GPR119 activity
EP2202223B1 (en) * 2007-10-18 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound as blood rbp4 lowering agent
CN101597278B (zh) 2008-06-04 2013-04-17 中国中化股份有限公司 酰胺类化合物及其制备与应用
GB0818241D0 (en) * 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
AR074318A1 (es) 2008-11-14 2011-01-05 Nycomed Gmbh Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias.
WO2010141550A2 (en) * 2009-06-04 2010-12-09 Wyeth Llc 11-beta hsd1 inhibitors
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2575815A4 (en) 2010-06-04 2013-12-25 Albany Molecular Res Inc GLYCIN TRANSPORTER 1 INHIBITORS, METHODS OF MAKING THE SAME, AND USES THEREOF
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2726470B1 (en) * 2011-07-01 2015-04-29 reMynd NV 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JP6339416B2 (ja) * 2014-05-28 2018-06-06 国立大学法人 名古屋工業大学 光学活性スルホンアミド誘導体の製造方法
CN104974084A (zh) * 2015-07-19 2015-10-14 佛山市赛维斯医药科技有限公司 一类胺基二吡啶叔醇结构的11β-HSD1抑制剂及其用途
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
WO2018140599A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
KR20200010306A (ko) 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Kras의 공유적 억제제
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
GB201713780D0 (en) * 2017-08-29 2017-10-11 E-Therapeutics Plc Modulators of hedgehog (Hh) signalling pathway
CA3107168A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
WO2020117972A1 (en) * 2018-12-04 2020-06-11 The Board Of Regents Of The University Of Texas System Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer
CN111943893B (zh) * 2019-05-17 2024-07-26 南京爱德程医药科技有限公司 4,7-二氮杂螺[2,5]辛烷类化合物的合成方法
FI3770201T3 (fi) * 2019-07-22 2023-08-14 Evonik Operations Gmbh Polymeerinen anioneja johtava kalvo
CN114667285B (zh) 2019-09-26 2025-08-08 诺华股份有限公司 抗病毒吡唑并吡啶酮化合物
EP4081509A4 (en) * 2019-12-24 2024-01-03 Zydus Lifesciences Limited NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA
JP2024534781A (ja) 2021-08-18 2024-09-26 ケモセントリックス，インコーポレイティド Ｃｃｒ６阻害剤としてのアリールスルホニル（ヒドロキシ）ピペリジン
CA3229226A1 (en) 2021-08-18 2023-02-23 Chemocentryx, Inc. Aryl sulfonyl compounds as ccr6 inhibitors
WO2025085848A1 (en) * 2023-10-20 2025-04-24 Arrepath, Inc. Antibacterial compounds
WO2025171035A1 (en) * 2024-02-06 2025-08-14 Corvus Pharmaceuticals, Inc. Itk inhibitors and uses thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2875205A (en) * 1959-02-24 Chj-chj
ZA813332B (en) * 1980-06-21 1982-05-26 Pfizer Larvicides and isecticides
JPS6081168A (ja) * 1983-10-13 1985-05-09 Asahi Chem Ind Co Ltd アミジン誘導体
FR2553414B1 (fr) 1983-10-18 1986-08-14 Choay Sa Nouveaux benzenesulfonamides n-cyclises, leur procede de preparation et leur utilisation comme substance active de compositions pharmaceutiques
US4857644A (en) 1988-06-09 1989-08-15 American Home Products Corporation Aryl sulfonopiperazines as anti-inflammatory agents
WO1993012086A1 (fr) * 1991-12-11 1993-06-24 Ss Pharmaceutical Co., Ltd. Derive d'arylamide
EP0661266A1 (en) 1993-12-27 1995-07-05 Toa Eiyo Ltd. Substituted cyclic amine compounds as 5HT2 antagonists
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
EP0891334A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
JP2000513711A (ja) 1996-04-18 2000-10-17 メルク エンド カンパニー インコーポレーテッド 癌の治療法
WO1997045412A1 (en) 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer
CA2286239A1 (en) 1997-04-07 1998-10-15 Merck & Co., Inc. A method of treating cancer
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6673799B1 (en) 1998-09-22 2004-01-06 Yamanouchi Pharmaceutical Co. Ltd. Cyanophenyl derivative
AU1230100A (en) 1998-10-29 2000-05-22 Merck & Co., Inc. A method of treating endometriosis
US6465468B1 (en) * 1999-03-22 2002-10-15 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
JP2001328938A (ja) 2000-03-17 2001-11-27 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体を有効成分とする医薬
US6812861B1 (en) * 2000-06-16 2004-11-02 Baumuller Anlagen-Systemtechnik Gmbh & Co. Method for automatically generating several electrical pulses using numeric default values, in particular for stimulating an incremental encoder
AU2001288432A1 (en) 2000-09-01 2002-03-22 Icos Corporation Materials and methods to potentiate cancer treatment
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
GB0108591D0 (en) 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
HUP0401241A3 (en) 2001-08-21 2008-03-28 Merck Sharp & Dohme Novel cyclohexyl sulphones, process for their preparation and pharmaceutical compositions containing them
GB0120347D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
JP2005509677A (ja) 2001-11-22 2005-04-14 ビオヴィトルム・アクチボラゲット １型１１−ベータ−ヒドロキシステロイドデヒヒドロゲナーゼの阻害剤
IL160630A0 (en) 2001-11-22 2004-07-25 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA04007775A (es) 2002-03-13 2004-10-15 Janssen Pharmaceutica Nv Derivados de sulfonilo como novedosos inhibidores de la histona desacetilasa.
KR20050025189A (ko) 2002-07-27 2005-03-11 아스트라제네카 아베 화학 화합물
BR0315166A (pt) 2002-10-11 2005-08-16 Astrazeneca Ab Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento
AU2003276458A1 (en) 2002-11-07 2004-06-07 Astrazeneca Ab 2-oxo-ethanesulfonamide derivates
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
CA2521175A1 (en) 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
WO2004089416A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
SG145695A1 (en) 2003-07-29 2008-09-29 Xenon Pharmaceuticals Inc Pyridyl derivatives and their use as therapeutic agents
KR20060037409A (ko) 2003-07-30 2006-05-03 제논 파마슈티칼스 인크. 피페라진 유도체 및 그의 치료제로서의 용도
EP2316825A1 (en) 2003-07-30 2011-05-04 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1703908A4 (en) 2003-12-22 2009-07-08 Amgen Inc ARYLSULFONAMIDE COMPOUNDS AND RELATED APPLICATIONS
IN2012DN03023A (es) 2004-01-26 2015-07-31 Merck Sharp & Dohme
US20050277629A1 (en) 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
AR048523A1 (es) * 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
US7402704B2 (en) 2004-04-14 2008-07-22 Amgen Inc. Arylsulfones and uses related thereto
AU2005250336B2 (en) 2004-04-20 2011-06-09 Amgen, Inc. Arylsulfonamides and uses as hydroxysteroid dehydrogenase
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
EP1758884A2 (en) 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
JP2008504276A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
EP1758882A4 (en) 2004-06-24 2008-01-23 Incyte Corp AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS
CA2584502A1 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
JP2008504278A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
US20060009491A1 (en) 2004-06-24 2006-01-12 Incyte Corporation Amido compounds and their use as pharmaceuticals
CA2570637A1 (en) 2004-06-24 2006-02-02 Wenqing Yao N-substituted piperidines and their use as pharmaceuticals
JP4809339B2 (ja) 2004-06-28 2011-11-09 エフ．ホフマン−ラ ロシュ アーゲー ピリミジン誘導体
MX2007000040A (es) 2004-06-30 2007-03-07 Schering Corp N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas.
BRPI0513864A (pt) * 2004-07-28 2008-05-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, sua utilização e método para o tratamento e/ou profilaxia de enfermidades
US20060025445A1 (en) 2004-08-02 2006-02-02 Xiang Jason S 11-Beta HSD1 inhibitors
CN101080226A (zh) 2004-08-10 2007-11-28 因塞特公司 酰氨基化合物及它们作为药物的用途
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
JP4958787B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GT200600046A (es) 2005-02-09 2006-09-25 Terapia de combinacion
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2007055942A2 (en) * 2005-11-03 2007-05-18 Merck & Co., Inc. Substituted nicotinamide compounds
AU2006326540A1 (en) 2005-12-14 2007-06-21 Amgen Inc. Diaza heterocyclic sulfonamide derivatives and their uses
KR20080087833A (ko) 2005-12-21 2008-10-01 쉐링 코포레이션 히스타민 ｈ３ 길항제로서 유용한 페녹시피페리딘 및 이의유사체
PA8713501A1 (es) 2006-02-07 2009-09-17 Wyeth Corp INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
US8110562B2 (en) 2006-07-19 2012-02-07 University Of Tennessee Research Foundation Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof

Also Published As

Publication number Publication date
AU2007212429A1 (en) 2007-08-16
US20070219198A1 (en) 2007-09-20
WO2007092435A3 (en) 2007-12-27
EP1981848A2 (en) 2008-10-22
CN101400653A (zh) 2009-04-01
PA8713501A1 (es) 2009-09-17
WO2007092435A2 (en) 2007-08-16
KR20080093072A (ko) 2008-10-17
US7632838B2 (en) 2009-12-15
JP2009526059A (ja) 2009-07-16
PE20071232A1 (es) 2008-02-18
IL193157A0 (en) 2009-02-11
GT200800151A (es) 2008-11-03
AR059355A1 (es) 2008-03-26
US20100029648A1 (en) 2010-02-04
TW200800898A (en) 2008-01-01
BRPI0707537A2 (pt) 2011-05-03
RU2008132333A (ru) 2010-03-20
NO20083492L (no) 2008-10-28
CA2641609A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
CR10186A (es) Inhibidores de 11-beta-hsd1
BRPI0717460A2 (pt) Composições de inibidores de chk1
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
BRPI0719204A2 (pt) Inibidores de hdac
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
LTC2178888I2 (lt) Proteazomos inhibitoriai
EP2036552A4 (en) SENESCENCE INHIBITOR
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
EP1981519A4 (en) PROTEASE INHIBITION
DK2402317T3 (da) DGAT-inhibitor
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
MA32938B1 (fr) Composes organiques
BRPI0814797A2 (pt) Inibidores dna-pk
EP2305306A4 (en) NEURO INVASION INHIBITOR
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
CR9301S (es) Cuerpo de grifo
EP2051707A4 (en) Plasma kallikrein INHIBITORS
BRPI0719389A2 (pt) Derivados de hidantoína utilizados como inibidores de mmp
DK1948678T3 (da) Forbindelser til enzyminhibering
ATE503744T1 (de) Nicht-nukleosidische reverse-transkriptase-hemmer
HN2007006799A (es) Analogos de biaril piperazinil-piridina sustituidos
EP2229363A4 (en) Renin Inhibitors
EP2007383A4 (en) HEMMER OF PROTEIN PRENYL TRANSFERASES
EP2237793A4 (en) CATHEPSIN-B INHIBITORS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)